Epigenetic therapy through the CRISPR-dCas9 method can accurately target and reactivate zygote arrest 1 (ZAR1), allowing it to regain its role as a tumor suppressor Deutschmeyer and Richter, (2020). This evidence concerns the gene ZAR1 and neoplasm.